XENE

Xenon Pharmaceuticals Inc. (XENE) - 10-K Summary

Business Context and Reporting Period

Company: Xenon Pharmaceuticals Inc.
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Xenon is a neuroscience-focused biopharmaceutical company developing therapeutics for epilepsy and neuropsychiatric disorders. The company has no approved products and generates no product revenue. Its primary asset is azetukalner, a Kv7 potassium channel opener in Phase 3 clinical trials for focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS), major depressive disorder (MDD), and bipolar depression (BPD). The company also maintains an early-stage pipeline for pain and epilepsy.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: Revenue in 2025 consisted entirely of a $7.5 million milestone payment from Neurocrine Biosciences. The company has no debt obligations other than operating leases.

Material Changes vs. Prior Period

• Revenue Recognition: The company recognized $7.5 million in collaboration revenue in 2025, compared to zero in 2024 and 2023. This was triggered by the Phase 1 initiation of NBI-921355 under the Neurocrine collaboration.
• Expense Growth: Total operating expenses increased by $101.3 million (36%) year-over-year. R&D expenses rose by $90.5 million, driven by ongoing Phase 3 studies for azetukalner in epilepsy and depression, and the advancement of pain programs (XEN1701, XEN1120).
• Interest Income Decline: Interest income decreased by $15.1 million to $26.8 million due to lower average balances of marketable securities and lower market yields.
• Capital Raising: The company raised $112.2 million net from common share issuances under its "at-the-market" (ATM) program in 2025, compared to $12.1 million in 2024.

Guidance, Outlook, and Risks

Clinical Milestones & Outlook:

• Epilepsy (FOS): Topline data for the Phase 3 X-TOLE2 study is expected in the first half of March 2026. The X-TOLE3 study (global) continues enrollment.
• Depression (MDD): Phase 3 studies (X-NOVA2, X-NOVA3) are enrolling; topline data for X-NOVA2 is expected in H1 2027.
• Liquidity: Management expects existing cash and marketable securities ($586.0 million) to fund operations for at least the next 12 months.

Key Risks & Contingencies:

• Profitability: The company has incurred significant losses since inception and expects to continue doing so for the foreseeable future. It has no products approved for commercial sale.
• Capital Requirements: Future funding will be required to complete clinical trials and prepare for commercialization. Failure to raise capital could force delays or termination of programs.
• Regulatory & Clinical Risk: Success depends on the outcome of Phase 3 trials. Failure to demonstrate efficacy or safety in these pivotal studies would materially harm the business.
• Collaboration Dependence: Future revenue is contingent on milestone payments and royalties from the Neurocrine Biosciences collaboration, which are not guaranteed.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $586.0 million cash balance against the projected burn rate for the upcoming Phase 3 readouts and potential commercialization build-out.
• Phase 3 Data Readout: Monitor the March 2026 topline data release for the X-TOLE2 FOS study, which is the most immediate catalyst for regulatory approval.
• Neurocrine Collaboration: Review the terms of the Neurocrine agreement to understand the probability and timing of future milestone payments beyond the $7.5 million already recognized.
• ATM Program Usage: Track the utilization of the $350 million ATM program to assess dilution risks and management's confidence in the stock price.
• Patent Expiry: Confirm the patent landscape for azetukalner, with key U.S. patents expected to expire between 2039 and 2040.